These spatial data combined with studies from Figures 5E–5H, demonstrate that IT CXCL9/10-DC vaccination enhances T cell recruitment to the tumor margin, and the addition of anti-PD-1 promotes sustained proliferation and effector functions of tumor-infiltrating CD4+ and CD8+ T cells, which likely mediate the antitumor efficacy of combination therapy (Figures 6A and 6B). This evidence concerns the gene CXCL9 and neoplasm.